Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 5
1986 5
1987 7
1988 10
1989 9
1990 18
1991 9
1992 17
1993 15
1994 7
1995 13
1996 9
1997 6
1998 14
1999 13
2000 21
2001 27
2002 21
2003 17
2004 21
2005 28
2006 24
2007 25
2008 33
2009 27
2010 21
2011 15
2012 34
2013 31
2014 31
2015 46
2016 31
2017 45
2018 44
2019 41
2020 48
Text availability
Article attribute
Article type
Publication date

Search Results

694 results
Results by year
Filters applied: . Clear all
Page 1
Pathogenesis and clinical features of psoriasis.
Griffiths CE, Barker JN. Griffiths CE, et al. Lancet. 2007 Jul 21;370(9583):263-271. doi: 10.1016/S0140-6736(07)61128-3. Lancet. 2007. PMID: 17658397 Review.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Blauvelt A, et al. Among authors: griffiths cem. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. Lancet. 2017. PMID: 28478972 Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: griffiths ce. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Parisi R, et al. Among authors: griffiths ce. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. J Invest Dermatol. 2013. PMID: 23014338 Free article. Review.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. Among authors: griffiths ce. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Free article. Clinical Trial.
Psoriasis: epidemiology, clinical features, and quality of life.
Langley RG, Krueger GG, Griffiths CE. Langley RG, et al. Among authors: griffiths ce. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii18-23; discussion ii24-5. doi: 10.1136/ard.2004.033217. Ann Rheum Dis. 2005. PMID: 15708928 Free PMC article. Review.
Clinical and genetic differences between pustular psoriasis subtypes.
Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F. Twelves S, et al. Among authors: griffiths cem. J Allergy Clin Immunol. 2019 Mar;143(3):1021-1026. doi: 10.1016/j.jaci.2018.06.038. Epub 2018 Jul 21. J Allergy Clin Immunol. 2019. PMID: 30036598 Free PMC article.
Definition of treatment goals for moderate to severe psoriasis: a European consensus.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Mrowietz U, et al. Among authors: griffiths ce. Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21. Arch Dermatol Res. 2011. PMID: 20857129 Free PMC article.
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Griffiths CEM, et al. J Drugs Dermatol. 2018 Aug 1;17(8):826-832. J Drugs Dermatol. 2018. PMID: 30124721 Clinical Trial.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. Among authors: griffiths ce. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
694 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback